Stocks Analysis by Michael Lebowitz covering: Eli Lilly and Company, Novo Nordisk A/S. Read Michael Lebowitz's latest article on Investing.com
)), just completed a clinical side-by-side trial. After 72 weeks of testing on 750 obese or overweight adults with at least one medical problem, Eli Lilly came out ahead by a substantial margin. Per Eli Lilly:. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.
As shown, in both the average monthly cycle and the average Presidential election year, the market tends to weaken mid-month as mutual funds make their annual distributions. Furthermore, the BLS data has been revised to a much larger extent than ADP. The second graph below shows that small and medium-sized businesses continue to see weakening trends. To wit, small business payrolls fell by 17k, the fourth decline in the last five months. This is likely a function of higher interest rates having a much more significant impact on smaller companies.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Scott Bessent Plans to Reshape the US Economy with His 3-3-3 RuleMarket Overview Analysis by Michael Lebowitz covering: S&P 500, Eli Lilly and Company, Mastercard Inc, Thermo Fisher Scientific Inc. Read Michael Lebowitz's latest article on Investing.com
Read more »
Eli Lilly shares jump on two big updates and Jim Cramer is so here for itThe Biden administration proposed a rule change that would expand access to Eli Lilly's Zepbound. And an obesity drug competitor released disappointing results.
Read more »
Zepbound results in more weight loss than Wegovy in trial, Eli Lilly saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Stocks making the biggest moves midday: JetBlue, Eli Lilly, Pure Storage, Salesforce and moreThese are the stocks posting the largest moves in midday trading.
Read more »
Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks riseEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trialEli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
Read more »